MX2014014818A - Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel.

Info

Publication number
MX2014014818A
MX2014014818A MX2014014818A MX2014014818A MX2014014818A MX 2014014818 A MX2014014818 A MX 2014014818A MX 2014014818 A MX2014014818 A MX 2014014818A MX 2014014818 A MX2014014818 A MX 2014014818A MX 2014014818 A MX2014014818 A MX 2014014818A
Authority
MX
Mexico
Prior art keywords
inflammatory diseases
treating skin
skin inflammatory
route
administration
Prior art date
Application number
MX2014014818A
Other languages
English (en)
Inventor
Joseph P St Laurent
Original Assignee
Olatec Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Ind Llc filed Critical Olatec Ind Llc
Publication of MX2014014818A publication Critical patent/MX2014014818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a una composición farmacéutica y método para el tratamiento de enfermedades inflamatorias de la piel, tales como dermatitis, psoriasis, y acné, mediante la administración de 3-metanosulfonilpropionitrilo, o una sal o solvato de éste, farmacéuticamente aceptable. El método alivia los síntomas de la enfermedad tratada. El compuesto activo puede ser administrado por una ruta sistémica o una ruta tópica. La administración tópica es la ruta de administración que se prefiere.
MX2014014818A 2012-06-05 2013-06-03 Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel. MX2014014818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655936P 2012-06-05 2012-06-05
PCT/US2013/043921 WO2013184586A1 (en) 2012-06-05 2013-06-03 Method for treating skin inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2014014818A true MX2014014818A (es) 2015-02-12

Family

ID=49712530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014818A MX2014014818A (es) 2012-06-05 2013-06-03 Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel.

Country Status (10)

Country Link
US (3) US9078869B2 (es)
EP (1) EP2854784B1 (es)
JP (1) JP6185575B2 (es)
KR (1) KR102112883B1 (es)
CN (1) CN104411303B (es)
AU (1) AU2013271836B2 (es)
BR (1) BR112014030285B1 (es)
CA (1) CA2875052C (es)
MX (1) MX2014014818A (es)
WO (1) WO2013184586A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102112883B1 (ko) 2012-06-05 2020-05-19 오라텍 세라퓨틱스 엘엘씨 피부 염증 질환의 치료 방법
EP3110412B1 (en) 2014-02-25 2018-10-31 Olatec Therapeutics LLC 4-benzylsulfonyl-2-butenenitrile
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
MX2019007942A (es) * 2017-01-06 2019-09-04 Olatec Therapeutics Llc Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares.
EP3768384A4 (en) * 2018-03-21 2021-11-17 Olatec Therapeutics LLC METHOD OF TREATMENT OF MELANOMAS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040896B1 (en) * 1978-08-22 1984-04-25 Sumitomo Chemical Company, Limited Synthesis of amides
DE3041155A1 (de) * 1980-10-31 1982-06-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen
US5175192A (en) 1984-03-19 1992-12-29 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
KR100294084B1 (ko) 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
AU2002254396A1 (en) * 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US7423064B2 (en) 2004-09-24 2008-09-09 Olatec Industries, Llc Composition for treating bacterial, viral, fungal diseases, inflammation and pain
EP1996014B1 (en) 2006-03-20 2010-11-17 Olatec Industries LLC Composition for treating bacterial, viral, fungal diseases, inflammation and pain
WO2008101064A1 (en) * 2007-02-14 2008-08-21 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
BRPI1014528A2 (pt) * 2009-03-18 2016-04-05 Olatec Ind Llc compostos para tratamento de inflamação e dor
BR112013014583A2 (pt) * 2010-12-15 2016-09-20 Olatec Ind Llc composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
KR102112883B1 (ko) 2012-06-05 2020-05-19 오라텍 세라퓨틱스 엘엘씨 피부 염증 질환의 치료 방법

Also Published As

Publication number Publication date
JP2015518886A (ja) 2015-07-06
US9592217B2 (en) 2017-03-14
EP2854784A1 (en) 2015-04-08
CN104411303B (zh) 2017-09-05
US20160256430A1 (en) 2016-09-08
EP2854784A4 (en) 2016-01-20
BR112014030285B1 (pt) 2022-03-29
CN104411303A (zh) 2015-03-11
US9078869B2 (en) 2015-07-14
CA2875052C (en) 2020-07-14
US9278082B2 (en) 2016-03-08
CA2875052A1 (en) 2013-12-12
KR20150018851A (ko) 2015-02-24
BR112014030285A2 (pt) 2017-06-27
US20160008314A1 (en) 2016-01-14
US20150080476A1 (en) 2015-03-19
BR112014030285A8 (pt) 2021-06-22
AU2013271836B2 (en) 2018-03-01
AU2013271836A1 (en) 2015-01-22
WO2013184586A1 (en) 2013-12-12
EP2854784B1 (en) 2019-12-04
KR102112883B1 (ko) 2020-05-19
JP6185575B2 (ja) 2017-08-23

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
PH12016500077B1 (en) Therapeutically active compounds and their methods of use
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
MX358016B (es) Derivados de n-acildipeptido y sus usos.
MX2018000421A (es) Composiciones de retinoides topicos.
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
MY192033A (en) Method of dosing and use of soft anticholinergic esters
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2014014818A (es) Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel.
WO2012050831A3 (en) Combination treatment for dermatological conditions
NZ716034A (en) Treatment of inflammatory lesions of rosacea with ivermectin
AU2019268085A1 (en) Compound of glycosaminoglycan, preparation method and use thereof
WO2014153385A3 (en) Methods of treating metabolic disorders
WO2014070696A3 (en) Treatment of chronic dermal inflammatory with norketotifen
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
TN2015000142A1 (en) Use of pidotimod to treat psoriasis
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
WO2013121300A3 (en) Methods for treating psoriasis and vascular inflammation
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
CY1116609T1 (el) Τοπικη συνθεση η οποια περιλαμβανει ενα κορτικοστεροειδες ως δραστικο συστατικο